AR060768A1 - Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. - Google Patents

Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.

Info

Publication number
AR060768A1
AR060768A1 ARP070101952A ARP070101952A AR060768A1 AR 060768 A1 AR060768 A1 AR 060768A1 AR P070101952 A ARP070101952 A AR P070101952A AR P070101952 A ARP070101952 A AR P070101952A AR 060768 A1 AR060768 A1 AR 060768A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halogen
hydrogen
heteroaryl
Prior art date
Application number
ARP070101952A
Other languages
English (en)
Inventor
Yonghong Song
Zhaozhong J Jia
Robert M Scarborough
Anjali Pandey
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR060768A1 publication Critical patent/AR060768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que contienen dichos compuestos, para prevenir o tratar diversas condiciones caracterizadas por trombosis indeseada. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde Z se selecciona entre el grupo formado por formulas (2); R1 se selecciona entre el grupo formado por halogeno, alquilo C1-8, alquenilo C2-8 y alquinilo C2-8; R1a se selecciona entre el grupo formado por hidrogeno y alquilo C1-4; R2 y R3 se seleccionan en forma independiente entre el grupo formado por hidrogeno, halogeno, alquilo C1-4, SR4a, S(O)R4a, S(O)2R4a, COR4a, CO2R4a,CONR4aR4b, CN, y S(O)2NR4aR4b; R4 se selecciona entre el grupo formado por H, halogeno OR4a, SR4a, S(O)R4a, S(O)2R4a, NR4aR4b, CO2R4a, grupo de formulas (3), en donde cada uno de estos sistemas de anillos está opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados en forma independiente entre el grupo formado por halogeno, amino, oxo, alquilo C1-8, haloalquilo C1-8, hidroxi, alcoxi C1-8, heterocicloalquilo, heteroarilo y heteroaril-C1-4 alquilo; cada R4a o R4b es en forma independiente hidrogeno o alquilo C1-4, opcionalmente sustituido con entre 1 y 2 sustituyentes seleccionados en forma independiente entre el grupo formado por halogeno, hidroxilo, alcoxi, heterociclilo, oxo, amino y carboxilo; el subíndice n es un entero entre 0 y 2; R5 se selecciona entre el grupo formado por formulas (4) en donde cada uno de estos sistemas de anillos está opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados en forma independiente entre el grupo formado por halogeno, alquilo C1-8, haloalquilo C1-8, -NH-C(O)-alquilo C1-8, hidroxi, amino, oxo, alcoxi C1-8, heterocicloalquilo, heteroarilo y heteroaril-C1-4 alquilo, con la salvedad de que cuando R5 como en formula (5) es entonces no puede haber un sustituyente alquilo (o alquilo sustituido) en la posicion 5 del anillo R5; R6 se selecciona entre el grupo formado por hidrogeno, halogeno, y alquilo C1-4; R7 se selecciona entre el grupo formado por hidrogeno, alquilo C1-4, ciano, fenilo opcionalmente sustituido, y C(O)R9 en donde R9 es alquilo C1-4 o NH2; R8 se selecciona entre el grupo formado por hidrogeno y alquilo C1-4; la línea ondulada indica el punto de union con el resto de la molécula; o sales aceptables para uso farmacéutico, ésteres o prodrogas de los mismos.
ARP070101952A 2006-05-05 2007-05-04 Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. AR060768A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79795406P 2006-05-05 2006-05-05
US88366707P 2007-01-05 2007-01-05

Publications (1)

Publication Number Publication Date
AR060768A1 true AR060768A1 (es) 2008-07-10

Family

ID=38480433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101952A AR060768A1 (es) 2006-05-05 2007-05-04 Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.

Country Status (17)

Country Link
US (4) US7763608B2 (es)
EP (1) EP2016072B1 (es)
JP (1) JP5227311B2 (es)
KR (1) KR20090010098A (es)
CN (1) CN101490036B (es)
AR (1) AR060768A1 (es)
AU (1) AU2007247928B2 (es)
BR (1) BRPI0711296A2 (es)
CA (1) CA2651303A1 (es)
EA (1) EA015942B1 (es)
HK (1) HK1126490A1 (es)
IL (1) IL194891A (es)
MX (1) MX2008014193A (es)
NZ (1) NZ572418A (es)
TW (1) TW200813017A (es)
WO (1) WO2007131179A1 (es)
ZA (2) ZA200809362B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP2591784B1 (en) 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
US20080214495A1 (en) * 2005-07-08 2008-09-04 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
WO2007008146A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008057972A1 (en) * 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
US20080293704A1 (en) * 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
AU2008239659B2 (en) 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
EP2586439A1 (en) * 2007-05-02 2013-05-01 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
WO2009063029A2 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
ES2610145T3 (es) 2009-12-17 2017-04-26 Millennium Pharmaceuticals, Inc. Procedimientos de síntesis de inhibidores del factor Xa
US20110160250A1 (en) 2009-12-17 2011-06-30 Millennium Pharmaceuticals, Inc. Crystalline forms of a factor xa inhibitor
CA2784921A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
US20150224091A1 (en) 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
CN103242310A (zh) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
ES2746116T3 (es) * 2012-12-24 2020-03-04 Coagulant Therapeutics Corp Polipéptidos del Factor VII de corta acción
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
ES2663806T3 (es) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
CA2961981A1 (en) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
JP2018509426A (ja) * 2015-03-19 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 血栓症の治療のための因子ＸＩａ阻害剤としてのオキソピリジン誘導体
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CA2991261A1 (en) * 2015-07-06 2017-01-12 Bayer Cropscience Aktiengesellschaft Nitrogenous heterocycles as a pesticide
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10148678B2 (en) 2015-10-01 2018-12-04 The Boeing Company Cybersecurity system with differentiated capacity to deal with complex cyber attacks
TWI752421B (zh) * 2015-12-16 2022-01-11 日商日本曹達股份有限公司 芳基唑化合物及有害生物防除劑
CN105753804A (zh) * 2016-04-15 2016-07-13 大连信科化工有限公司 一种制备3-吗啉酮的方法
WO2019105871A1 (de) 2017-11-29 2019-06-06 Bayer Aktiengesellschaft Stickstoffhaltige heterocyclen als schädlingsbekämpfungsmittel
WO2019215076A1 (de) * 2018-05-08 2019-11-14 Bayer Aktiengesellschaft Verfahren zur herstellung stickstoffhaltiger heterocyclen
CN108715584B (zh) * 2018-06-22 2021-06-25 四川大学华西医院 以n-吡啶-2-(1h)-腈亚氨为母核的荧光分子及其制备与应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US254036A (en) * 1882-02-21 Measuring-faucet
US162690A (en) * 1875-04-27 Improvement in valves for steam-engines
US153876A (en) * 1874-08-04 Improvement in carbureting apparatus
US185092A (en) * 1876-12-05 Improvement in check-rowers
US293704A (en) * 1884-02-19 Windmill
US241233A (en) * 1881-05-10 Wind-wheel
US42015A (en) * 1864-03-22 Improvement in saddles
US298806A (en) * 1884-05-20 Bag and twine holder
US66615A (en) * 1867-07-09 Steering apparatus
US749217A (en) * 1904-01-12 Ho model
US279845A (en) * 1883-06-19 John d
US125052A (en) * 1872-03-26 Improvement in apparatus for checking horses
US100193A (en) * 1870-02-22 John ross
US51578A (en) * 1865-12-19 Improvement in cigar-machines
US98119A (en) * 1869-12-21 Improved rocking and easy chair
US29064A (en) * 1860-07-10 Lowering and detaching ships boats
US112039A (en) * 1871-02-21 Improvement in plow-colters
US259924A (en) * 1882-06-20 Sand-band
US186810A (en) * 1877-01-30 Improvement in machines for making metal fellies
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US63113A (en) * 1867-03-19 smith
US197929A (en) * 1877-12-11 Improvement in boots and shoes
US697135A (en) * 1901-03-07 1902-04-08 Henry W Scott Antislipping device.
US756037A (en) * 1903-03-21 1904-03-29 Angus Morrison Press-rack.
US836536A (en) * 1906-02-12 1906-11-20 Eagle Lock Co Suit-case lock.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US5919779A (en) 1997-08-11 1999-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
US6644367B1 (en) * 1999-07-23 2003-11-11 Scholle Corporation Connector assembly for fluid flow with rotary motion for connection and disconnection
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
KR100760434B1 (ko) 1999-09-17 2007-10-04 밀레니엄 파머슈티컬스 인코퍼레이티드 벤즈아미드 및 관련된 Ｘａ 인자의 억제제
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
ATE368643T1 (de) 2001-03-30 2007-08-15 Millennium Pharm Inc Faktor xa benzamidin inhibitoren
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
ES2180456B1 (es) 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
AU2003221322A1 (en) 2002-03-07 2003-09-16 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
JP3090812U (ja) 2002-06-18 2002-12-26 アルプス電気株式会社 高周波モジュール
WO2004101531A1 (en) 2003-04-29 2004-11-25 Dr. Reddy's Laboratories Ltd. Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
WO2004106329A2 (en) 2003-06-03 2004-12-09 Dr. Reddy's Laboratories Ltd. Novel antiinfective compounds and their pharmaceutical compositions
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7022695B2 (en) 2003-10-09 2006-04-04 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of Factor Xa
WO2005035528A2 (en) 2003-10-14 2005-04-21 Dr. Reddy's Laboratories Ltd. Triazole derivatives as antibacterial agents
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004031258A1 (de) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen
US20060002099A1 (en) * 2004-06-30 2006-01-05 Stoneham Edward B Electromagnetic shield assembly
CA2596444A1 (en) 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DK1951254T3 (da) 2005-11-03 2012-05-07 Portola Pharm Inc (4-(6-halo-7-substitueret-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl)¨-5-chlorthiophen-2-yl-sulfonylureaer og former og fremgangsmåder der er relateret dertil
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
WO2008073670A2 (en) 2006-12-08 2008-06-19 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
US20080293704A1 (en) 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
WO2008121721A2 (en) 2007-03-28 2008-10-09 Portola Pharmaceuticals, Inc. Targeted delivery and expression of procoagulant hemostatic activity
AU2008239659B2 (en) 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
EP2586439A1 (en) 2007-05-02 2013-05-01 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法

Also Published As

Publication number Publication date
US20120088795A1 (en) 2012-04-12
EA200802288A1 (ru) 2009-04-28
CA2651303A1 (en) 2007-11-15
WO2007131179A1 (en) 2007-11-15
JP5227311B2 (ja) 2013-07-03
ZA201007095B (en) 2011-06-29
JP2009536218A (ja) 2009-10-08
KR20090010098A (ko) 2009-01-28
TW200813017A (en) 2008-03-16
CN101490036A (zh) 2009-07-22
BRPI0711296A2 (pt) 2011-08-23
EP2016072A1 (en) 2009-01-21
US20070259924A1 (en) 2007-11-08
ZA200809362B (en) 2012-01-25
US20090030045A1 (en) 2009-01-29
US7763608B2 (en) 2010-07-27
IL194891A (en) 2014-06-30
HK1126490A1 (en) 2009-09-04
EA015942B1 (ru) 2011-12-30
US8349873B2 (en) 2013-01-08
AU2007247928B2 (en) 2013-06-13
US7767697B2 (en) 2010-08-03
CN101490036B (zh) 2013-07-17
US20100249117A1 (en) 2010-09-30
AU2007247928A1 (en) 2007-11-15
EP2016072B1 (en) 2014-07-16
MX2008014193A (es) 2009-03-31
NZ572418A (en) 2011-08-26
US20110118244A2 (en) 2011-05-19
IL194891A0 (en) 2009-08-03
US8063077B2 (en) 2011-11-22

Similar Documents

Publication Publication Date Title
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR088449A1 (es) Benzilindazoles sustituidos
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
ECSP12011867A (es) Derivados bencimidazol-imidazol
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
AR078786A1 (es) Derivados de la cromenona
AR070079A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
CU20090070A7 (es) Nuevos derivados de sulfonamida como antagonistas de la bradiquinina
AR058776A1 (es) Compuesto de piridina condensado
AR051388A1 (es) Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato

Legal Events

Date Code Title Description
FB Suspension of granting procedure